Want to see AU:OSL full AI Analyst Report?
OncoSil Medical Ltd (OSL) AI Stock Analysis
OncoSil Medical Ltd
(ASX:OSL)
The overall score is driven primarily by very weak financial performance, with entrenched operating losses, heavy cash burn, and reliance on external funding despite improving revenue and narrowed losses. Secondary pressure comes from a bearish technical setup showing subdued momentum and oversold conditions rather than a clear recovery trend. Valuation further anchors the score in the lower range, as the negative P/E and lack of dividend support frame the stock as a high-risk, speculative medical device investment rather than a fundamentally attractive opportunity.
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 24.96M
- Dividend Yield
- ―
- Average Volume (3M)
- 126.12K
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 1.45
- Revenue Growth
- 43.92%
- EPS Growth
- 65.23%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
OncoSil Medical Ltd Business Overview & Revenue Model
Company Description
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the...
OncoSil Medical Ltd Financial Statement Overview
Summary
Financial performance is very weak, with deeply negative margins, heavy operating and net losses, and persistently negative cash flow, partially offset by low leverage and recent revenue growth and narrowed losses.
Income Statement
24NegativeBalance Sheet
47NeutralCash Flow
21Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.68M | 1.68M | 1.17M | 516.63K | 367.68K | 231.79K |
| Gross Profit | -6.20M | -6.20M | -1.08M | -993.00K | -1.22M | -6.73M |
| EBITDA | -14.36M | -14.36M | -15.06M | -11.94M | -11.17M | -11.41M |
| Net Income | -10.86M | -10.86M | -15.10M | -11.91M | -11.34M | -10.73M |
Balance Sheet | ||||||
| Total Assets | 10.31M | 10.31M | 7.15M | 6.72M | 11.47M | 13.07M |
| Cash, Cash Equivalents and Short-Term Investments | 6.48M | 6.48M | 5.11M | 4.50M | 9.39M | 11.28M |
| Total Debt | 14.78K | 14.78K | 69.92K | 70.67K | 170.81K | 304.21K |
| Total Liabilities | 5.31M | 5.31M | 4.04M | 1.98M | 1.59M | 1.91M |
| Stockholders Equity | 5.00M | 5.00M | 3.10M | 4.74M | 9.88M | 11.16M |
Cash Flow | ||||||
| Free Cash Flow | -10.47M | -10.47M | -12.08M | -11.02M | -11.37M | -10.12M |
| Operating Cash Flow | -10.47M | -10.47M | -12.06M | -10.82M | -11.32M | -10.11M |
| Investing Cash Flow | -1,455 | -1,455 | -14.96K | -197.06K | -57.82K | -5,832 |
| Financing Cash Flow | 11.86M | 11.86M | 12.73M | 6.13M | 9.49M | 9.16M |
OncoSil Medical Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OSL, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.89, and below the 200-day MA of 0.78, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 35.52 is Neutral, neither overbought nor oversold. The STOCH value of 9.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OSL.
OncoSil Medical Ltd Peers Comparison
Overall Rating
AU:PNV75Outperform
AU:ARX51Neutral
AU:EMV50Neutral- AU:OSL39.2Underperform
AU:IPD39Underperform
AU:CYC36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:PNV | 75Outperform | AUD 625.21M | 85.38 | 8.45% | ― | 12.94% | -44.50% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ARX | 51Neutral | AUD 190.25M | 45.83 | 4.96% | ― | 19.23% | ― |
| AU:EMV | 50Neutral | AUD 139.67M | -16.46 | -46.84% | ― | ― | 20.40% |
| AU:OSL | 39Underperform | AUD 24.96M | -1.42 | -245.90% | ― | 43.92% | 65.23% |
| AU:IPD | 39Underperform | AUD 14.66M | -0.34 | -259.31% | ― | 14.85% | -1.74% |
| AU:CYC | 36Underperform | AUD 53.44M | -2.66 | -62.14% | ― | 12.05% | -31.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:OSL | OncoSil Medical Ltd | 0.68 | -0.58 | -46.12% | |
| AU:PNV | Polynovo Limited | 0.91 | -0.36 | -28.46% | |
| AU:IPD | Impedimed Limited | 0.01 | -0.02 | -62.16% | |
| AU:CYC | Cyclopharm Limited | 0.42 | -0.21 | -33.07% | |
| AU:ARX | Aroa Biosurgery Ltd | 0.55 | -0.25 | -31.25% | |
| AU:EMV | EMvision Medical Devices Ltd. | 1.50 | -0.31 | -17.02% |
OncoSil Medical Ltd Corporate Events
OncoSil Wins Landmark U.S. FDA Nod as Revenue Surges and Global Expansion Accelerates
OncoSil Medical Ltd, an Australian medical device maker focused on targeted treatments for pancreatic cancer and distal cholangiocarcinoma, is advancing global commercialisation of its OncoSil radiation implant. The company is targeting specialised o...
OncoSil study shows full local control and surgical gains in advanced pancreatic cancer
OncoSil Medical has reported new clinical data from a prospective single-centre study in Greece evaluating its OncoSil™ P-32 microparticle implant combined with gemcitabine and nab-paclitaxel in 17 patients with unresectable locally advanced pa...
OncoSil Discloses Lapse of Director Performance Rights
OncoSil Medical Ltd reported a minor change in the equity interests of Director Nigel Lange, who holds ordinary shares, options, and performance rights in the company. The disclosure forms part of the firm’s ongoing adherence to ASX listing rul...
OncoSil Performance Rights Expire, Trimming Potential Equity Dilution
OncoSil Medical Ltd has reported the cessation of 24,156 performance rights that expired unexercised on 25 October 2026. The lapse of these convertible securities slightly reduces the company’s potential dilution from incentive instruments, wit...
OncoSil boosts real-world evidence as OSPREY registry expands in Europe
OncoSil Medical has reported updated real-world data from its OSPREY Registry, presented at the European Association of Nuclear Medicine congress, covering 88 patients with unresectable locally advanced pancreatic cancer treated at 19 centres in Spai...
OncoSil Medical Sets November Date for Virtual AGM, Urges Early Proxy Voting
OncoSil Medical Ltd has called its Annual General Meeting for 18 November 2026, to be held virtually at 11:00 a.m. AEDT, and has dispatched the notice of meeting, access letter and proxy forms to shareholders. The AGM documentation is available via t...
OncoSil joins EU-backed PALACROS trial in capital-efficient push into pancreatic cancer research
OncoSil Medical is deepening its European footprint through participation in the PALACROS research programme, a Horizon Europe and EU Mission on Cancer-backed initiative focused on locally advanced pancreatic cancer. The company’s European subs...
OncoSil sets 2026 AGM date and director nomination deadline
OncoSil Medical Ltd, a specialist in interventional oncology devices, has developed its single-use OncoSil brachytherapy implant to deliver targeted beta radiation to tumours while limiting exposure to surrounding organs. The device has secured CE Ma...
OncoSil Medical to Release 41,067 Escrowed Shares as Global Oncology Push Continues
OncoSil Medical has notified the market that 41,067 ordinary shares will be released from voluntary escrow on 30 September 2026, shares that were originally issued to directors in lieu of part of their cash fees. The move modestly increases the trada...
OncoSil raises $4m in compliant share placement to support global oncology push
OncoSil Medical Ltd has completed a $4 million placement, issuing 4 million fully paid ordinary shares at $1.00 each to institutional and sophisticated investors. The company has lodged a cleansing notice confirming ongoing compliance with key Corpor...
OncoSil Medical Expands ASX-Quoted Share Base
OncoSil Medical Ltd has applied for quotation of 1,812,663 new fully paid ordinary shares on the ASX, with an issue date of September 10, 2026. The additional securities, arising from the exercise of options or conversion of other instruments, modest...
OncoSil Medical Seeks ASX Quotation for 4 Million New Shares
OncoSil Medical Ltd has applied for quotation of 4,000,000 new ordinary fully paid shares on the ASX, with an issue date of September 10, 2026. The newly quoted securities arise from previously announced transactions, indicating a further expansion o...
OncoSil Secures Key ISO Step Toward Scaling Production of Cancer Device
OncoSil Medical’s Australian contract manufacturer Cyclotek has secured ISO 13485 certification, a key international quality standard for medical device quality management systems. The milestone advances plans to establish manufacturing of the...
OncoSil hits 100-patient milestone in key Spanish cancer market
OncoSil Medical has marked a commercial milestone in Spain, announcing that the 100th patient has been treated with its OncoSil™ device for unresectable locally advanced pancreatic cancer, a procedure performed at Hospital HM Sanchinarro in Mad...
OncoSil Medical Plans ASX Share Placement to Raise Capital
OncoSil Medical Ltd has announced a proposed placement of up to 4,000,000 ordinary fully paid shares on the ASX. The new securities are scheduled for issue on 10 September 2026, subject to ASX processes and quotation.The capital raising via this shar...
OncoSil Medical Raises $5.6m to Drive Cancer Device Commercialisation
OncoSil Medical has secured $5.6 million in new capital from its three largest institutional investors through a $4.0 million share placement at a premium to its last traded price and the early exercise of $1.6 million in listed options. The funding...
OncoSil Seeks CMS Pass-Through Status to Support U.S. Launch of Cancer Device
OncoSil Medical has submitted an application to the U.S. Centers for Medicare & Medicaid Services for Transitional Pass-Through Payment status for its OncoSil™ device, following recent FDA Humanitarian Device Exemption approval for treating...
OncoSil Seeks US Medicare Pass-Through Status for Targeted Cancer Device
OncoSil Medical has moved to strengthen its U.S. commercial strategy by submitting an application to the Centers for Medicare & Medicaid Services for Transitional Pass-Through payment status for its OncoSil™ device. The filing follows recen...
OncoSil lodges updated ASX corporate governance statement for FY 2026
OncoSil Medical has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and current as of 28 August 2026. The filing, together with the completed Appendix 4G, out...
OncoSil narrows annual loss as revenue and other income surge
OncoSil Medical Ltd reported a 43.9% increase in revenue from ordinary activities to $1.68 million for the year ended 30 June 2026, alongside a sharp 678.2% rise in other income and interest revenue to $3.54 million, reflecting stronger income stream...
OncoSil Seeks ASX Quotation for Small Issue of New Shares
OncoSil Medical Ltd has applied for quotation of 500 new ordinary fully paid shares on the Australian Securities Exchange, with the securities issued on 17 August 2026. The small issuance, arising from the exercise or conversion of existing instrumen...
OncoSil Flags FDA Milestone While Stressing Investor Caution
OncoSil Medical has prepared an investor webinar titled “FDA Approval: A New Chapter for OncoSil,” highlighting the U.S. regulator’s clearance as a key milestone for the company. The presentation emphasises that it is informational...
OncoSil Wins Landmark U.S. FDA Approval for Rare Bile Duct Cancer Device
OncoSil Medical has secured U.S. FDA Humanitarian Device Exemption approval for its OncoSil device to treat unresectable, non-metastatic distal cholangiocarcinoma, a rare bile duct cancer with limited options and a median overall survival of 6.7 mont...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026